Advertisement

NLS Lytix Biopharma

Clinical Trials - June 14, 2022

Lytix Biopharma announces new data

Lytix Biopharma has announced data from its ATLAS-IT-04 trial in patients with metastatic soft tissue sarcoma (STS). The data from this Phase II proof of concept study shows that LTX-315 in combination with Adoptive Cell Therapy (ACT) was able to stabilize the disease in 3 out of 4 fully treated patients in this hard-to-treat patient […]

In a new job - May 25, 2021

Lytix Biopharma strengthens its board of directors

Lytix Biopharma have announced the nomination of four new board members. The four are the Swedish citizens, PhD Marie-Louise Fjällskog and PhD Evelina Vågesjö, the Norwegian citizen Kjetil Hestdal and the US citizen Jayson Rieger. They will all supplement the present board. Read more: Lytix Biopharma prepares for listing on Euronext Growth Oslo “I’m very […]

Clinical Trials - May 10, 2021

Lytix Biopharma announces positive data

Lytix Biopharma has announced promising data results from a phase I study of its lead candidate LTX-315. The findings were published in Clinical Cancer Research. “A major and persistent challenge in today’s cancer treatment is lack of tumor infiltrating T cells in the majority of cancer patients, making it difficult for the immune system to […]

Agreement - April 13, 2021

Lytix Biopharma in agreement with Arctic University of Norway

The company enters into an exclusive license agreement with the university for a class of new drug candidates and forms a strategic partnership with Aurelius Biotherapeutics. Lytix Biopharma, in collaboration with a research team at the Arctic University of Norway (UiT), has developed a new group of drug candidates, which can combat cancer cells through […]

Clinical Trials - January 20, 2021

Lytix Biopharma receives FDA clearance to initiate Phase II study

Lytix Biopharma has announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for LTX-315, an oncolytic molecule in development for various solid tumors. “This is a significant milestone for Lytix Biopharma, as it clears a path for further clinical development towards market approval in the US, […]

Agreement - August 12, 2020

Lytix Biopharma enters milestone agreement

Lytix Biopharma licenses its lead candidate LTX-315, an oncolytic peptide based immunotherapy, to Verrica Pharmaceuticals, for the treatment of dermatologic oncology indications. “With aggregate payments of more than $110M” Lytix is entitled to receive an up-front payment, contingent regulatory milestones based on achievement of specified development goals, and sales milestones, with aggregate payments of more […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.